RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies

Immune checkpoint inhibitors (ICI) are commonly associated with thyroid immune-related adverse events, yet the mechanism has not been fully elucidated. We aimed to further explore the mechanism of ICI-induced thyroid dysfunction by assessing changes induced in the thyroid transcriptome by ICI treatm...

Full description

Bibliographic Details
Main Authors:	Rena Pollack, Joshua Stokar, Natan Lishinsky, Irina Gurt, Naomi Kaisar-Iluz, Merav E. Shaul, Zvi G. Fridlender, Rivka Dresner-Pollak
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	International Journal of Molecular Sciences
Subjects:	immune checkpoint inhibitors anti PD-1 thyroid immune related adverse events transcriptome
Online Access:	https://www.mdpi.com/1422-0067/24/13/10526

Similar Items

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
by: Adi Horesh, et al.
Published: (2023-04-01)

Hepatic adropin is regulated by estrogen and contributes to adverse metabolic phenotypes in ovariectomized mice
by: Joshua Stokar, et al.
Published: (2022-06-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Tumor-Derived Factors Differentially Affect the Recruitment and Plasticity of Neutrophils
by: Ludovica Arpinati, et al.
Published: (2021-10-01)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
by: Jiawen Qian, et al.
Published: (2018-10-01)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
by: David Escors, et al.
Published: (2022-10-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

PD-1/PD-L1 pathway: A double-edged sword in periodontitis
by: Xiaowei Liu, et al.
Published: (2023-03-01)

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
by: Rosa Lombardi, et al.
Published: (2022-02-01)

The Bilateral Interplay between Cancer Immunotherapies and Neutrophils’ Phenotypes and Sub-Populations
by: Naomi Kaisar-Iluz, et al.
Published: (2022-02-01)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
by: Nicholas J. Bevins, et al.
Published: (2022-11-01)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
by: Fei Tang, et al.
Published: (2018-05-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
by: Yunzhou Pu, et al.
Published: (2022-05-01)

The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components
by: Peng Zhang, et al.
Published: (2023-11-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
by: Daehyun Kim, et al.
Published: (2020-12-01)

The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis
by: Michał Adamczyk, et al.
Published: (2023-06-01)

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
by: Günther Schönrich, et al.
Published: (2019-06-01)

SIRT1 haplo-insufficiency results in reduced cortical bone thickness, increased porosity and decreased estrogen receptor alpha in bone in adult 129/Sv female mice
by: Hanna Artsi, et al.
Published: (2022-12-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
by: Tao Huang, et al.
Published: (2022-12-01)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
by: You-Cheng Zhang, et al.
Published: (2023-01-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
by: Yunjiao Wu, et al.
Published: (2024-03-01)

PD-L1 Dysregulation in COVID-19 Patients
by: Francesco Sabbatino, et al.
Published: (2021-06-01)

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
by: Phyu P. Aung, et al.
Published: (2019-05-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021-03-01)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
by: Yuwei Hao, et al.
Published: (2022-01-01)

Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis
by: Kang CHEN, et al.
Published: (2020-11-01)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
by: Xuan Zhao, et al.
Published: (2022-08-01)

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
by: Reem Saleh, et al.
Published: (2020-06-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
by: Wei Zhang, et al.
Published: (2019-05-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)